Medicare Enrolled

Dr. Amirali Popatia, M.D.

Optician · Richmond, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
1603 MAIN ST, Richmond, TX 77469
2813442273
In practice since 2006 (19 years)
NPI: 1952349920 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Popatia from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Popatia? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Popatia

Dr. Amirali Popatia is an optician in Richmond, TX, with 19 years in practice. Based on federal Medicare data, Dr. Popatia performed 27,306 Medicare services across 873 unique beneficiaries.

Between the years covered by Open Payments, Dr. Popatia received a total of $18,397 from 71 pharmaceutical and/or device companies across 829 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Popatia is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 3% volume in TX$ $18,397 industry payments

Medicare Practice Summary

Medicare Utilization ↗
27,306
Medicare services
Top 3% in TX for optician
873
Unique beneficiaries
$19
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,437 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Denosumab injection (Prolia/Xgeva)9,600$19$50
Dexamethasone injection (steroid)4,120$0$2
Epoetin alfa injection (Retacrit) for anemia3,960$6$40
Infusion, normal saline solution, 250 cc1,064$1$15
Injection, leucovorin calcium, per 50 mg1,025$3$10
Injection, granisetron hydrochloride, 100 mcg930$0$5
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less785$22$75
Injection, fluorouracil, 500 mg773$2$25
Injection of additional new drug or substance into vein543$12$75
Injection, magnesium sulfate, per 500 mg500$1$2
5% dextrose/normal saline (500 ml = 1 unit)462$1$15
Administration of chemotherapy into vein, 1 hour or less458$97$325
Injection, diphenhydramine hcl, up to 50 mg396$1$2
Infusion into a vein for hydration, each additional hour353$10$50
Office visit, established patient (30-39 min)348$91$175
Injection, fosnetupitant 235 mg and palonosetron 0.25 mg318$340$1,200
Administration of additional new drug or substance into vein, 1 hour or less311$49$200
Administration of chemotherapy into vein, each additional hour298$21$150
Office visit, established patient, complex (40-54 min)268$133$200
Drug injection, under skin or into muscle209$11$50
Office visit, established patient (20-29 min)209$66$125
Administration of additional new drug or substance into vein using push technique152$42$125
Injection of drug or substance into vein81$28$100
Infusion into a vein for hydration, 31-60 minutes55$25$100
Office visit, established patient (10-19 min)34$42$100
New patient office visit, complex (60-74 min)32$168$350
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less22$48$120
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
8.3% high complexity
85.0% medium
6.7% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$18,397
Total received (2018-2024)
Avg $2,628/year across 7 years
Top 10% in TX for optician
71
Companies
829
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,732 (85.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,208 (12.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$457 (2.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,948
2023
$2,600
2022
$2,453
2021
$2,522
2020
$2,247
2019
$4,367
2018
$2,259

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Genentech USA, Inc.
$2,918
Amgen Inc.
$1,354
Merck Sharp & Dohme Corporation
$1,296
E.R. Squibb & Sons, L.L.C.
$1,216
AstraZeneca Pharmaceuticals LP
$1,031
Lilly USA, LLC
$869
Merck Sharp & Dohme LLC
$836
PFIZER INC.
$608
Daiichi Sankyo Inc.
$575
Eisai Inc.
$464
GENZYME CORPORATION
$377
GlaxoSmithKline, LLC.
$350
Ipsen Biopharmaceuticals, Inc
$342
EISAI INC.
$291
Spectrum Pharmaceuticals Inc.
$276
Seagen Inc.
$276
AVEO Pharmaceuticals, Inc.
$264
Astellas Pharma US Inc
$242
Coherus Biosciences Inc.
$227
Boehringer Ingelheim Pharmaceuticals, Inc.
$227
Regeneron Healthcare Solutions, Inc.
$216
TESARO, Inc.
$194
TerSera Therapeutics LLC
$194
Bayer HealthCare Pharmaceuticals Inc.
$193
Teva Pharmaceuticals USA, Inc.
$183
Gilead Sciences, Inc.
$176
Organon LLC
$168
Celgene Corporation
$167
PUMA BIOTECHNOLOGY, INC.
$157
JAZZ PHARMACEUTICALS INC.
$153
Seattle Genetics, Inc.
$145
Taiho Oncology, Inc.
$137
Mylan Institutional Inc.
$133
Aveo Pharmaceuticals, Inc.
$133
Puma Biotechnology, Inc.
$133
EMD Serono, Inc.
$119
Dendreon Pharmaceuticals LLC
$116
Exelixis Inc.
$107
Mirati Therapeutics, Inc.
$104
Novartis Pharmaceuticals Corporation
$102
Pharmacyclics LLC, An AbbVie Company
$96
Celltrion USA Inc.
$93
Myriad Genetic Laboratories, Inc.
$91
Foundation Medicine, Inc.
$86
TAIHO ONCOLOGY, INC.
$83
Amneal Pharmaceuticals LLC
$67
Sirtex Medical Inc
$64
Blueprint Medicines Corporation
$62
Bayer Healthcare Pharmaceuticals Inc.
$57
Deciphera Pharmaceuticals Inc.
$56
Heron Therapeutics, Inc.
$50
Jazz Pharmaceuticals Inc.
$48
Helsinn Therapeutics (U.S.), Inc.
$44
Clovis Oncology, Inc.
$43
Pharmacosmos Therapeutics Inc.
$40
Janssen Biotech, Inc.
$31
BeiGene USA, Inc.
$31
Myovant Sciences Inc.
$27
ARRAY BIOPHARMA INC
$27
Curium US LLC
$25
Adaptive Biotechnologies Corporation
$25
Progenics Pharmaceuticals, Inc.
$22
Immunocore Limited
$22
R-Pharm US LLC
$21
Stemline Therapeutics Inc.
$21
Telix Pharmaceuticals
$20
Janssen Pharmaceuticals, Inc
$19
SANOFI-AVENTIS U.S. LLC
$18
Incyte Corporation
$14
Kyowa Kirin, Inc.
$12
Kite Pharma, Inc.
$12
Top 3 companies account for 30.3% of total payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · ALIMTA · AVASTIN · Abraxane · Alecensa · Avastin · BAVENCIO · BENDEKA · BLENREP · BRAFTOVI · BRUKINSA · Bavencio · CALQUENCE · CINVANTI · COSELA · CYRAMZA · Cabometyx · Columvi · Detectnet · ELITEK · ENHERTU · ERBITUX · Enhertu · Erleada · FASLODEX · FOTIVDA · FOUNDATIONONE · FULPHILA · Fulphila · GAVRETO · GAZYVA · GILOTRIF · Halaven · Herceptin · IBRANCE · ILLUCCIX · IMFINZI · INFLECTRA · INLYTA · INQOVI · INREBIC · Imbruvica · Ixempra · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MONJUVI · MVASI · MYCHOICE CDX · MYRISK · Monoferric · NERLYNX · NEXPLANON · Nerlynx · Neulasta · Nexavar · Nplate · ONTRUZANT · OPDIVO · OPDUALAG · ORGOVYX · Ogivri · Onivyde · Orserdu · PADCEV · POTELIGEO · PROVENGE · PYLARIFY · Padcev · Perjeta · PreciseTumor · Prolia · QINLOCK · RETEVMO · ROLVEDON · Revlimid · Rituxan · Rubraca · SIR-Spheres Microspheres · SOMATULINE DEPOT · SUSTOL · SUTENT · Stivarga · TABRECTA · TAGRISSO · TALZENNA · TECENTRIQ · TRUSELTIQ · TUKYSA · Tazverik · Tecentriq · Trodelvy · Truxima · Udenyca · VEGZELMA · VERZENIO · VYXEOS · Vectibix · Venclexta · WELIREG · XALKORI · XARELTO · XGEVA · Xermelo · ZEJULA · ZEPZELCA · Zoladex · Zynrelef · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (86%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 10% for optician in TX.

Equivalent to $67 per 100 Medicare services performed
Looking for a optician in Richmond?
Compare opticians in the Richmond area by procedure volume, costs, and industry payment transparency.
Browse opticians nearby

Geographic Context

Opticians within 10 mi
319
Per 100K population
37.1
County median income
$113,409
Nearest hospital
OAKBEND MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Popatia is a mixed practice specialist, with above-average Medicare volume (top 3% in TX), and high industry engagement (low-engagement, top 10%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Popatia experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Popatia performed 9,600 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Popatia receive payments from pharmaceutical companies?
Yes. Dr. Popatia received a total of $18,397 from 71 companies across 829 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Popatia's costs compare to other opticians in Richmond?
Dr. Popatia's average Medicare payment per service is $19. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Popatia) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →